Advertisement
News
Advertisement

Tivorsan makes key DMD therapy development

Tue, 12/28/2010 - 7:34am
Mass High Tech: The Journal of New England Technology

Tivorsan Pharmaceuticals, a protein therapeutics firm in Providence, R.I., has shown that mice with Duchenne Muscular Dystrophy have had improved muscle function due to biglycan protein, according to a news release today from the company.

The company is preparing to bring the protein to human clinical studies.

Duchenne Muscular Dystrophy is a muscle loss disorder that affects one in 3,500 newborn boys, the company reported, and is marked by a mutation of the dystrophin protein-encoded gene. The disease has no current treatments available.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading